Jonathan Zalevsky, Chief R&D Officer at NEKTAR THERAPEUTICS (NKTR), sold 1,721 shares at $35.69 ($58K) on 2025-09-04, disclosed to the SEC on 2025-09-08.
Scheduled sale ($58k) by Chief R&D Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.43 | 793 | $26K | 44.6% |
| 2 | $33.60 | 432 | $15K | 25.2% |
| 3 | $34.41 | 189 | $7K | 11.3% |
| 4 | $35.69 | 307 | $11K | 19.0% |
| Total | $33.52 avg | 1,721 | $58K | 100% |
| Filing → |
| NKTR | SELL | 2026-06-17 | $336K | — | Filing → |
| NKTR | SELL | 2026-05-21 | $13K | — | Filing → |
| NKTR | SELL | 2026-02-20 | $13K | — | Filing → |